{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:14:42Z","timestamp":1792300482871,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bbmt.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T13:10:52Z","timestamp":1515417052000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Roni","family":"Tamari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday R.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Castro-Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2018.01.001_bib0010","first-page":"S25","article-title":"Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score","volume":"12","author":"Appelbaum","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0020","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.bbmt.2011.05.001","article-title":"Improved survival after allogeneic hematopoietic stem cell transplantation in recent years: a single-center study","volume":"17","author":"Remberger","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0040","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0045","first-page":"3996","article-title":"T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities","volume":"95","author":"Champlin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0050","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0055","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V91.3.1083","article-title":"T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease","volume":"91","author":"Papadopoulos","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbmt.2011.01.005","article-title":"T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies","volume":"17","author":"Jakubowski","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2012.09.003","article-title":"T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease","volume":"19","author":"Goldberg","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0070","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbmt.2008.02.006","article-title":"Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings","volume":"14","author":"Castro-Malaspina","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0075","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bbmt.2015.07.010","article-title":"CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse","volume":"21","author":"Tamari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0080","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(80)92394-6","article-title":"Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin","volume":"2","author":"Reisner","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0085","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V67.5.1302.1302","article-title":"et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation","volume":"67","author":"de Witte","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V72.4.1168.1168","article-title":"Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial","volume":"72","author":"Wagner","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1703154","article-title":"Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation","volume":"28","author":"Urbano-Ispizua","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0100","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbmt.2013.02.018","article-title":"Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bmt.2014.302","article-title":"Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts","volume":"50","author":"Hobbs","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbmt.2016.12.633","volume":"23","author":"Barba","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0120","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0125","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","article-title":"T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin","volume":"110","author":"Jakubowski","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0130","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","article-title":"Characteristics of CliniMACS system CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303","volume":"18","author":"Keever-Taylor","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0135","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4613-1493-6_5","article-title":"Chronic graft-versus-host disease","volume":"50","author":"Sullivan","year":"1990","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0145","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0150","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0155","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood.V73.5.1340.1340","article-title":"Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts","volume":"73","author":"Keever","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0160","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V100.6.2235","article-title":"Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations","volume":"100","author":"Lewin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3324\/haematol.2010.029702","article-title":"Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age","volume":"96","author":"Castermans","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0170","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0175","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0180","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12026-007-0059-2","article-title":"Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants","volume":"38","author":"O'Reilly","year":"2007","journal-title":"Immunol Res"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0185","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","article-title":"Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells","volume":"40","author":"Mackinnon","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0195","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","volume":"19","author":"Clancy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0200","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0205","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0210","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0215","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0225","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/TP.0000000000000649","article-title":"Contribution of revised International Prognostic Scoring System cytogenetics to predict outcome after allogeneic stem cell transplantation for myelodysplastic syndromes: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"99","author":"Gauthier","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0230","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.bbmt.2014.06.022","article-title":"Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation","volume":"20","author":"Oran","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0235","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.bbmt.2015.01.017","article-title":"Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome","volume":"21","author":"Ustun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0240","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0245","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0250","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/sim.6205","article-title":"Use of composite endpoints in clinical trials","volume":"33","author":"Sankoh","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0255","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.001_bib0260","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","article-title":"Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups","volume":"101","author":"Inamoto","year":"2016","journal-title":"Haematologica"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:11Z","timestamp":1761058871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118300016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1083879118300016"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.001","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}